• Non-adherent wound contact layer
• Excess wound fluid is transpired away from the wound bed, reducing the risk of maceration
• Promotes rapid wound closure, less potential for leakage and odor
• Provides an effective barrier to bacteria penetration and reduces bacterial load (in-vitro)
• Product is easy to apply, can be removed in one piece and is designed in sizes and shapes appropriate for target wound types
• Prevents healing tissue from growing into the dressing, minimizing pain on removal
• Top film becomes more breathable in the presence of fluid
• Conformable and comfortable
• Maintains a moist wound interface
• Waterproof

ALLEVYN* Ag Non-Adhesive Dressing is indicated for exudate absorption and the management of partial- to full-thickness wounds.

For external use only.
ALLEVYN* Ag Non-Adhesive is not compatible with oxidizing agents (eg, EUSOL) or hydrogen peroxide, as these can break down the absorbent polyurethane component of the dressing.
ALLEVYN* Ag Non-Adhesive dressings are not intended to provide treatment for infected wounds. ALLEVYN* Ag Non-Adhesive may be used on infected wounds being managed in accordance with institutional clinical protocols for infection abatement as an adjunct to the standard treatment regimen to provide a barrier to bacterial penetration.
ALLEVYN* Ag Non-Adhesive may not be compatible with topical antimicrobials.
Reddening of the skin around the wound may be observed. This may be related to irritation of fragile skin or wound exudates remaining in contact with normal skin for prolonged periods of time. If reddening or sensitization occur, discontinue use.
Avoid contact with electrodes or conductive gels during electronic measurements (eg, EEG and ECG).
When ALLEVYN* Ag Non Adhesive is used on a patient during MRI (Magnetic Resonance Imaging) examination, some warming may be experienced.
ALLEVYN* Ag Non-Adhesive is not compatible with oil-based products, such as petrolatum.
ALLEVYN* Ag Non-Adhesive is not suitable for use on cavity wounds but may be used over cavity wounds as a secondary dressing.
As with all products containing silver sulfadiazine the following precautions should be noted, especially when covering a large surface area with the dressing:
1. Use caution in patients with significant hepatic or renal impairment,
2. Use caution in individuals known to have glucose-6-phosphate dehydrogenase deficiency,
3. Effects of systemically administered drugs may be altered. This can especially apply to oral hypoglycemic agents and to phenytoin. In the case of these drugs, it is recommended that blood levels should be monitored, as their effect can be potentiated.